Over the past year, Novo Nordisk‘s shares have surged 79%, largely due to the success of its semaglutide drugs. The unprecedented demand has even led to the company limiting its marketing efforts as it scales up its manufacturing capabilities.

Aside from treating diabetes and obesity, semaglutide could potentially be used to treat cardiovascular disease, metabolic dysfunction-associated steatohepatitis (MASH), and addiction disorders.

See Also: Agile Says It’s On Track To Hit 25−25−30 Million Net Annual Revenue After A Strong Performance In Its Seco

Precedence Research estimates the value of the cardiovascular disease market at over $162 billion. Novo Nordisk is set to request regulatory approval for a new indication of semaglutide in reducing cardiovascular risks before the end of the year.

The company is also investigating the use of semaglutide in treating MASH in a phase 3 clinical trial. The results are expected in mid-2028, but promising early data could result in a sneak peek.

Lastly, semaglutide could potentially be used to treat addiction disorders, a market anticipated to be worth over $60 billion by 2029, according to Fortune Business Insights. Several ongoing studies are investigating this potential use.

Read Next: Dental Savings Plans Give The 76% Of Seniors Without Dental Insurance A Way To Manage The Costs Of Oral C

Image By Natalia Varlei On Shutterstock